[{"id":"591144ff-4c63-46d7-a621-a1ad32a91744","acronym":"MERECA","url":"https://clinicaltrials.gov/study/NCT02432846","created_at":"2022-08-22T14:56:54.274Z","updated_at":"2024-07-02T16:36:05.101Z","phase":"Phase 2","brief_title":"Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)","source_id_and_acronym":"NCT02432846 - MERECA","lead_sponsor":"Immunicum AB","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Intuvax (ilixadencel)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 01/31/2021","study_completion_date":" 01/31/2021","last_update_posted":"2022-08-22"}]